期刊
EXPERT OPINION ON INVESTIGATIONAL DRUGS
卷 24, 期 3, 页码 393-399出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.2015.1001490
关键词
Alzheimer's disease; beta amyloid; clinical trials; inflammation; receptor for advanced glycation endproducts
资金
- Banner Sun Health Research Institute
- National Institutes of Aging [AG 019610]
Introduction: Reduction in the deposition of amyloid beta (A beta) has been the primary target for Alzheimer's disease (AD) therapeutics recently, but in clinical trials this approach has generally been unsuccessful. A common feature of AD pathology is a complex inflammatory component that could be a target for treatment. One feature of this inflammation has been the involvement of the receptor for advanced glycation endproducts (RAGE), whose ligands include advanced glycation-endproduct-modified proteins as well as lipids and A beta, which are found at elevated levels in AD brains. Areas covered: In this article, the authors describe the key features of RAGE and how it could have a role in AD pathogenesis. They also summarize experimental animal and clinical data that demonstrate the therapeutic effect of RAGE inhibition and consider what these findings mean for human disease. Expert opinion: RAGE has multiple ligands, including Ab, that are increased in AD brains. Inhibiting RAGE-ligand interactions without activating receptor signaling can reduce multiple pathological pathways relevant for AD. Several RAGE inhibitors and modulators are now being tested as therapeutics for AD. Recent Phase II studies have established the good safety and tolerability of TTP448 with some evidence of positive benefit at lower dose. This suggests that further studies are required.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据